Targeting regulatory T cells in tumors (Q38703565)

5 September 2017

Targeting regulatory T cells in tumors (English)

1 reference

5 September 2017

Chang Liu

1

1 reference

5 September 2017

Creg J Workman

series ordinal

2

1 reference

5 September 2017

Dario A A Vignali

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

20 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

283

1 reference

5 September 2017

14

1 reference

5 September 2017

2731-2748

1 reference

Hallmarks of Cancer: The Next Generation

5 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

How regulatory T cells work

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

FOXP3 and scurfy: how it all began

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

A Distinct Function of Regulatory T Cells in Tissue Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Extrathymically generated regulatory T cells control mucosal TH2 inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Induced CD4+Foxp3+ regulatory T cells in immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Interview: immunotherapeutic manipulation of the tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Foxp3+ regulatory T cells: differentiation, specification, subphenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Emerging strategies for cancer immunoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Aire-dependent thymic development of tumor-associated regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Feedback control of regulatory T cell homeostasis by dendritic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Cutting edge: regulatory T cells do not mediate suppression via programmed cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Interleukin-35: Expanding Its Job Profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Interleukin-35 Limits Anti-Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The role of regulatory T cells in cancer immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Metronomic chemotherapy: changing the paradigm that more is better

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Neuropilin 1: function and therapeutic potential in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Neuropilin-1 as Therapeutic Target for Malignant Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13656

21 January 2018

Identifiers

DOI

10.1111/FEBS.13656

1 reference

5 September 2017

1 reference